Is the business good?
How good a business is HAE?
Haemonetics Corporation earns 7.0% on the capital it employs against a 9.0% cost of capital, so growth costs more than it returns.
7.0%
Return on invested capital · cost of capital 9.0% · 2.0 points below what the capital costs: growth destroys value
- Operating margin
- 12%
Operating margin · Medical Devices median 11% · 12 months to Q4 2026
- Cash conversion
- 2.68×
Cash conversion · 0.85× a year ago · every dollar of reported profit arrived as cash, and more
- R&D as % of revenue
- 4.5%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2021 | 10% |
| FY2022 | 8.1% |
| FY2023 | 13% |
| FY2024 | 13% |
| FY2025 | 16% |
| FY2026 | 12% |
Details›
- Gross margin12 months to Q4 2026
- 59%
- Operating margin12 months to Q4 2026
- 12%
- Net margin12 months to Q4 2026
- 7.3%
- Free cash flow margin
- 20%
- R&D as % of revenue
- 4.5%
- Revenue, trailing twelve months
- $1.33B
- Free cash flow, trailing twelve months
- $260M
- Net income, trailing twelve months
- $97M
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- 7.0%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion from the cash flow statement.